Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors

By Masuda Kiyomi   Aoki Kazutaka   Kamiko Kazunari   Takihata Masahiro   Ito Yuzuru   Nagakura Mieko   Kawasaki Satsuki   Akema Noriko   Hasegawa Maki   Nakajima Shigeru   Shinoda Kazuaki   Toumura Shyoken   Tsunoda Seishi   Enomoto Hitoshi   Shimotomai Hidefumi   Terauchi Yasuo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1111-1118

Informa Healthcare

Access to resources Recommend Favorite

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

By Pratley Richard E  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 503-512

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis

By Abe Masanori   Okada Kazuyoshi   Maruyama Takashi   Maruyama Noriaki   Matsumoto Koichi  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 169-176

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

By Forst Thomas   Pfützner Andreas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 101-110

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A   Lamos Elizabeth M   Davis Stephen N  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite